14
total announcements
SAKAR.NS · 15 min delayed
Sakar Healthcare Limited
Sakar Healthcare Limited has received 14 oncology product new approvals in the EU, UK, and Canada with 7 business partners, enhancing its coverage in treating various cancer types.
Sakar Healthcare Limited
Sakar Healthcare Limited has submitted newspaper clippings of an advertisement addressed to shareholders, as per SEBI (LODR) Regulations, 2015.
Sakar Healthcare Limited
Sakar Healthcare Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 22, 2026, along with the Annual Report 2025-26.
Sakar Healthcare Limited
Sakar Healthcare Limited has informed the Exchange about Transcript of Con-Call for Q1 FY27 Earnings Conference Call, where the company discussed its operational and financial performance, highlighting growth in oncology business, market access, and product development.
Sakar Healthcare Limited
Sakar Healthcare Limited has published a newspaper advertisement addressed to shareholders, as per the SEBI (LODR) Regulations, 2015.
Sakar Healthcare Limited
Sakar Healthcare Limited has informed the National Stock Exchange of India Ltd. about the availability of the audio recording of the conference call for Q1FY27. The recording is available on the company's website at https://www.sakarhealthcare.com/audio/SAKAR-Earning-Audio-Call-Recording-Q1Y27.mp3.
Sakar Healthcare Limited
Sakar Healthcare Limited has informed the Exchange about Investor Presentation, disclosing un-audited financial results for Q1FY27. The company reported a 38% YoY growth in revenue, 67% YoY growth in EBITDA, and 120% YoY growth in PAT. The presentation highlights the company's expanding product portfolio, wider market access, and increasing export opportunities.
Sakar Healthcare Limited
Sakar Healthcare Limited has scheduled a conference call on July 29th, 2026, at 12:00 Noon IST to discuss their Q1 FY27 results.
Sakar Healthcare Limited
Sakar Healthcare Limited has announced its unaudited financial results for the quarter ended June 30, 2026, with a 38% YoY revenue growth and a 120% YoY increase in PAT.
Sakar Healthcare Limited
Sakar Healthcare Limited has announced its unaudited financial results for the quarter ended June 30, 2026, with revenue from operations at Rs. 7297.25 lakhs and total income at Rs. 7451.64 lakhs. The company has also announced the appointment of secretarial auditors and cost auditors, and the convening of its 22nd Annual General Meeting on September 22, 2026.
Sakar Healthcare Limited
Sakar Healthcare Limited has informed the Exchange about the intimation of Board Meeting for taking on record Unaudited Financial Results for the quarter ended on 30th June, 2026 and other matter.
Sakar Healthcare Limited
Cobra India (Mauritius) Limited has submitted a disclosure under Regulation 29(1) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, regarding the acquisition of 489,026 shares of Sakar Healthcare Limited, representing 2.0462% of the total voting capital.
Sakar Healthcare Limited
Sakar Healthcare Limited has submitted a certificate under Regulation 74 (5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th June 2026, confirming the dematerialization of securities and listing on stock exchanges.
Sakar Healthcare Limited
Sakar Healthcare Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.